Thymidine phosphorylase (TP; also known as plateletderived endothelial cell growth factor, PD-ECGF) is an angiogenic factor that is chemotactic for endothelial cells and has been found to induce neovascularization in vivo. TP is frequently overexpressed in human solid tumors, where its expression has been correlated with increased tumor microvessel density, invasion, and metastasis, and shorter patient survival. In this report, TP activity in the WiDr colon carcinoma cell line was found to be induced 100-fold by tumor necrosis factor (TNFa), a secretory product of activated macrophages that has indirect angiogenic activities. Increased TP activity was accompanied by increased TP mRNA levels and without an increase in mRNA stability. TNFa-induced TP mRNA levels were reduced by mithramycin, a DNA-binding transcription inhibitor specific for GC-rich sequences. Transcriptional regulation by TNFa was confirmed by transient transfection of WiDr with upstream TP sequences in a luciferase reporter construct. Deletion analysis of the reporter pinpointed two regions of the TP promoter with regulatory elements for both TNFainducible and basal expression, and they contained, respectively, three and one consensus binding sites for the Sp1-family of transcription factors. One additional region contributed only to basal TP expression, and it contained three Sp1 sites. TNFa-induced TP expression decreased when point mutations were made in three of the four Sp1 sites postulated to contribute to both basal and TNFa-inducible expression. Electrophoretic mobility shift assays further demonstrated binding of nuclear Sp1 to these three sites. Sp1-binding activity was also increased in cells treated with TNFa. These studies establish a role for Sp1 in the regulation of expression of the angiogenic factor TP in colon cancer WiDr cells.
Introduction
Thymidine phosphorylase (TP), also known as plateletderived endothelial cell growth factor (PD-ECGF), catalyzes the reversible conversion of thymidine to thymine and 2-deoxyribose-1-phosphate (Zimmerman and Seidenberg, 1964) . It is an angiogenic factor that was found to be chemotactic for endothelial cells in vitro and to induce neovascularization in several in vivo assays (Miyazono et al., 1987; Ishikawa et al., 1989; Sumizawa et al., 1993; Finnis et al., 1993) . Studies have shown that TP expression was frequently elevated in human solid tumors, including colorectal cancers, where its expression was correlated with increased tumor microvessel density, increased tumor invasion and metastasis, and shorter patient survival time (Takebayashi et al., 1996) . A more careful investigation of TP expression in colorectal and other cancers by immunohistochemistry revealed that TP was frequently highly expressed in the non-malignant infiltrating cells in the tumor, in some cases, in the absence of expression in the tumor neoplastic epithelium cells (Takahashi et al., 1996; Koukourakis et al., 1998; Lee et al., 1999; Engels et al., 1997; Takahashi et al., 1998; Shimaoka et al., 2000; van Triest et al., 2000) . In GI tumors, TP overexpression occurred more often in tumor-associated macrophages and other stromal cells (plasma cells and fibroblasts), when compared to the colon cancer epithelial cells. It has been speculated that the tumor cells can amplify their own angiogenic activity by recruiting or activating macrophages which express high levels of angiogenic factors (Polverini and Leibovich, 1984) .
Conversely, tumor-associated macrophages may contribute to angiogenesis indirectly by increasing the expression of angiogenic factors in tumor cells. Thus TP activity and mRNA expression could be induced in various tumor cell lines in vitro by the cytokines TNFa, IL-1a, IFN-a and IFN-g, and the expression of TNFa, IL-1a, and IFN-g were positively correlated with TP activity in vivo in colorectal carcinomas (Eda et al., 1993b; Schwartz et al., 1998; Tevaearai et al., 1992; Goto et al., 2001; Takebayashi et al., 1995) . Activated monocytes and macrophages are a major source of TNFa, and it was proposed that the angiogenic activity of macrophages was mediated primarily by TNFa (Beutler and Cerami, 1986; Leibovich et al., 1987) . TNFa has been shown to impact several phases of the angiogenic process: it stimulated migration of endothelial cells and induced capillary tube-like structures in vitro, and induced capillary blood vessel growth in rat and rabbit cornea and in the developing chick chorioallantoic membrane (Leibovich et al., 1987; Frater-Schroder et al., 1987; Rosenbaum et al., 1988) . However, TNFa also inhibited the proliferation of cultured endothelial cells and capillary growth in an in vitro angiogenesis model (Sato et al., 1986 (Sato et al., , 1987 . TNF and related cytokines could also mediate angiogenesis via actions on microenvironmental factors, including the induction of hypoxia or by the development of a reduced pH (Griffiths et al., 1997) . The various effects of TNFa on endothelial cell growth and new vessel formation suggest its involvement in more than one angiogenic pathway.
The intracellular mechanisms regulating TP gene expression are mostly not known. Sequence analysis reveals that the human TP gene is composed of ten exons dispersed over a 4.3-kb region, with the translation start codon in the exon 2 and stop codon within the polyadenylation signal in exon 10. The TP promoter lacks 'TATA' and 'CCAAT' boxes commonly found in eukarytotic promoters (Hagiwara et al., 1991) . It does, however, contain nine copies of binding motifs of the Sp-general transcription factor upstream of the transcription start site. IFNa induced TP overexpression in colon carcinoma cells through both transcriptional activation and increased mRNA stability. The transcriptional activation is mediated by increased nuclear factors binding to a putative IFN-a response element (Schwartz et al., 1998) . Another cytokine, IFN-g, also upregulated TP expression in U937 cells, a human monocytic cell line. Its induction of TP, however, seemed to be only through transactivation of TP promoter, and GAS elements in the TP promoter region conferred responsiveness to IFN-g stimulation (Goto et al., 2001) . In addition to their potential effects on the angiogenic actions of TP, cytokine-mediated TP expression also modulated the sensitivity of tumor cells to fluoropyrimidine cancer chemotherapeutic drugs (Schwartz et al., 1995; Sawada et al., 1998) . In this study, we characterized constitutive TP expression and the regulatory effects of TNFa on TP gene expression, including TP promoter cisregulatory elements and transcription factors which may mediate the actions of TNFa.
Results
TNFa increases TP enzyme activity and mRNA levels in a colon carcinoma cell line
The effect of TNFa on TP expression was examined in WiDr human colon carcinoma cell. TP activity and mRNA levels were low in untreated WiDr cells, but increased with TNFa treatment beginning at 12 h (Figure 1 ). Induction of TP activity, which was maximal at 48 h, was observed with TNFa concentrations as low as 2.5 ng/ml, and there was a greater than 10-fold maximal increase observed at a concentration of 20 ng/ml. The induction of TP enzymatic activity was accompanied by the increase in mRNA levels, which had a similar time-course and dose-dependent induction (Figure 1) .
To determine if a decreased rate of mRNA turnover might have contributed to the increased levels of TP mRNA seen in WiDr cells treated with TNFa, actinomycin D was used to inhibit mRNA synthesis, and the rate of TP mRNA degradation was measured. TP mRNA had a relatively long half-life in the WiDr cells (10 h), and TNFa did not increase the stability of TP mRNA, but rather appeared to reduce its half-life to 6 h ( Figure 2 ). Thus there was no correlation between TP mRNA levels and mRNA stability, suggesting the involvement of other mechanisms in the enhanced expression of the TP gene with TNFa treatment.
Transcriptional regulation of TP expression by TNFa
Mithramycin binds to GC-specific regions of DNA including G/C box sequences, consensus nucleotide binding sites for the transcription factor Sp1 (Kadonga et al., 1986) . This prevents subsequent Sp1 binding, and selectively inhibits the transcription of a number of genes (Blume et al., 1991; Greenwel et al., 1997; Ryuto . Cells were washed, sonicated, and extracts analysed for TP activity as described in Materials and methods. Data are means+s.e.m. from at least four experiments. RNA was extracted and analysed by RT -PCR using primers specific for TP or GAPDH, using conditions described in Materials and methods. Samples were run on agarose gels and stained with ethidium bromide. Preliminary studies confirmed that band intensities were proportional to the amount of cDNA used in the PCR reactions, using RNA from both control and treated cells et al., 1996) . We evaluated the effect of mithramycin on TNFa-induced expression of TP mRNA. As shown in Figure 3 , mithramycin blocked the TNFa-induced increase in TP mRNA in the WiDr cells in a concentration-dependent manner. Although mithramycin can reduce expression of a number of genes (including GAPDH, not shown), it had no effect on actin mRNA levels.
Functional analysis of the TP promoter 5'-flanking region More detailed analysis of critical elements in the TP promoter was done using a series of luciferase constructs containing unidirectionally deleted fragments. A 1.4-kb fragment from the 5'-flanking region and a part of exon 1 (nucleotides 71276 to +64) of the TP gene was cloned into a promoterless luciferase reporter vector, and transfected into the WiDr cells (Figure 4) . The upstream region of the human TP gene contains at least nine potential Sp1 binding sites, as well as single AP2 and NF1 sites. In contrast, there were no apparent AP1, Egr1, HIF1, or NF-kB sites located in the approximately 1.4-kb region examined. Based on the sensitivity of the TP mRNA to mithramycin, deletion analysis focused on the Sp1 sites, which were clustered in three groups of three sites (Figure 4) . Deletion of sequences spanning 71276 and 71134 had no effect on basal promoter activity, but a 30% decrease was seen when sequences from 71134 to 7487 (which contained three Sp1 sites) were removed. There was no change in promoter activity with loss of sequences 7487 to 7368 (which lacks an Sp1 site but contained the AP2 site), but deletion of the 7368 to 7155 region (containing three Sp1 sites labeled 1,2 and 3) caused an additional 50% loss of promoter activity. Deletion of an additional Sp1 site (from 7155 to 764), labeled site 4, resulted in the complete loss of promoter activity. These data are consistent with a role for Sp1 cis-elements in constitutive TP transcription.
Treatment of the transfected cells with TNFa (20 ng/ ml for 48 h) increased luciferase activity in the cells up to threefold, demonstrating that TP is transcriptionally regulated by TNFa, and that this region of the TP gene contains sequences which confer responsiveness to TNFa ( Figure 5 ). Deletion of sequences 5' to bp 7368 had no effect on the induction of promoter activity by TNFa, while deletion of sequences from 7368 to 7155 (which Figure 2 Effect TNFa on TP mRNA stability in WiDr cells. TP mRNA levels in control and TNFa-treated WiDr cells were determined by RT -PCR, as described in Materials and methods. Cells were first treated with 20 ng/ml TNFa for 24 h, followed by the addition of actinomycin D (10 mg/ml) for the indicated times. RNA was isolated and analysed by RT -PCR as described in Materials and methods. Data are averages of two determinations; correlation coefficients for RNA half-lives for control and TNFa-treated cells were 0.88 and 0.99, respectively Figure 3 Mithramycin blocks TNFa-induced increase in TP mRNA. TP mRNA levels were determined in cells treated for 24 h with TNFa and 0, 100, 200 or 400 nM mithramycin, as indicated. TP and actin mRNA were analysed by RT -PCR Figure 4 Transcriptional regulation of TP mRNA: TP promoter analysis of constitutive expression in WiDr cells. Plasmids containing various lengths of the 5'-upstream sequences of the human TP gene were cloned into a luciferase reporter construct and transiently transfected into WiDr cells, described in Materials and methods. Typically 1 mg of luciferase reporter vector was used with 10 ng of pRL-CMV internal control construct. The medium was replaced after 5 h, and after 72 h, the cells were harvested using 100 ml of passive lysis buffer. Luciferase activity was measured and activity is expressed relative to the internal control. Transfections were performed in triplicate, and data are the means+s.e.m. from four experiments. The deletion constructs are shown in the left panel, and are numbered relative to the transcription initiation site. The location of the putative cis regulatory elements are shown: vertical bars are the nine Sp1 consensus sequences, numbers 1 to 4 refer to the four Sp1 sites studied in further detail, and A and N refer to Ap2 and NF1 sites, respectively include Sp1 sites 1 to 3) and from 7155 to 764 (Sp1 site 4) each caused an approximately 40% reduction in TNFa-responsiveness. Thus the TP promoter sequence from 7368 to 764 contained crucial elements that were necessary for both constitutive expression and for induction by TNFa treatment of WiDr cells, while the sequence from 71134 to 7487 was involved only in constitutive TP expression. Sp1 sites in the former region were chosen for further analysis.
Point mutations in Sp1 sites eliminate TP promoter activity
To identify the role of specific Sp1 binding sites thought to contribute to both basal and TNFamediated expression, point mutations of each of the four Sp1 elements in the 7368 to 764 region were incorporated into the reporter constructs. In all four cases, the central GC in the consensus recognition site was changed to AT ( Figure 5 ). Mutation of Sp1 sites 1, 3 and 4, abolished most of the promoter activity in TNFa-treated WiDr cells, while mutation of site 2 had a much more modest effect on TNFa-induced promoter activity.
TNFa induced an increase in Sp1-binding activity in nuclear extracts
An electrophoretic mobility shift assay (EMSA) was used to assess the effect of TNFa on Sp1 binding activity. Although several complexes were observed when nuclear extracts were incubated with an endlabeled consensus Sp1 oligonucleotide (Figure 6 ), only one complex (indicated by the arrow) was judged to be likely Sp1-specific. This was based on the loss of the complex in the presence of excess unlabeled oligo (lane 3) and the selective loss of the band, and appearance of a supershift band, upon incubation with an anti-Sp1 antibody (lane 4). These changes were not seen with a point-mutated unlabeled oligo or a control lgG (data not shown); nor did an anti-Sp3 antibody affect the density of the band (lane 5). Further confirmation of the specificity of the binding would require DNase footprinting analysis. An increase in Sp1 binding activity was observed when the WiDr cells were treated with TNFa (lane 2 compared to lane 1). Sp1 belongs to a small family of transcription factors which have similar binding properties to Sp1, and the additional complexes seen in the blot, some of which are induced by TNFa, may represent an increase in expression of these transcription factors.
Nuclear Sp1 binds to sequences in the TP promoter
To verify that the Sp1 sites identified in luciferase transfection assays were capable of binding to Sp1, the EMSA assay was repeated, using as probes, TP sequences representing the four Sp1 sites labeled as 1 to 4 in Figure 3 , and mutated in Figure 5 . The oligonucleotides used were all the same length, and equal number of d.p.m. of labeled oligo were used in each assay. As illustrated in Figure 6 (lanes 6 -13), the largest amount of binding was seen with TP Sp1 site 1 oligo (TP-Sp1 1 ), with less binding to sites 3 and 4, and little binding to site 2. These observations were consistent with the mutation analysis of these same sites using the luciferase assay, in which mutation in site 2 had little effect on promoter activity. The pattern of binding was identical to that seen when the Sp1 consensus sequence was used as a probe (lanes 1 -5), i.e. same pattern of multiple bands observed, supershift seen with Sp1 but not Sp3 antibody (lanes 15 and 16), and an increase in binding activity in extracts from TNFa-treated cells.
Discussion
The expression of angiogenic factors in tumors, and particularly their upregulation during the progression to a malignant phenotype, plays a critical role in the neovascularization process (Folkman and Shing, 1992; Hanahan and Folkman, 1996) . Within tumors, angiogenic factors are elicited not only from the tumor cells themselves, but also from the variety of non-transformed cells which are integral components of the typical tumor. Thus tumor-associated macrophages, mast cells, and other inflammatory monocytes each can contribute individually to the angiogenic phenotype of a tumor. Further, it is likely that cytokine-mediated interactions between these cell types and with the Figure 5 Transcriptional regulation of TP mRNA: role of Sp1 in TNFa-induced expression. Transient transfections were done as described in the legend to Figure 4 , and 24 h later, cells were treated with or without 20 ng/ml TNFa for an additional 48 h. Reporter vectors included those used in Figure 4 (solid bars), or the 7368 and 7155 constructs in which a GC to AT mutation had been made in each of the putative Sp1 consensus sequences (hatched bars). One of these mutations, for Sp1 site 3, is illustrated in the box. Luciferase expression was first normalized based on the luciferase internal control, and then the ratio of expression in TNFa-treated cells was determined relative to untreated cells. Data are means+s.e.m. of four experiments tumor cells are of vital importance to the activation of critical angiogenic factors. Although the molecular mechanisms underlying some of these events have been described for well-studied angiogenic factors such as VEGF, much less is known about the regulation of expression of TP, an angiogenic factor that is widely overexpressed in human GI tumors.
In this study, we examined the interaction between TNFa and the angiogenic factor TP in human colon carcinoma WiDr cells, and found that TNFa increased TP activity and mRNA expression in a dose and timedependent manner. TNFa is a secretory product of activated macrophages that has multiple biological effects on tumor and endothelial cells, including the induction of apoptosis and angiogenesis in vivo, the latter most likely through indirect mechanisms (Leibovich et al., 1987) . A number of genes that can mediate angiogenesis have been shown to be induced by TNFa, including bFGF, plasminogen activator, platelet-activating factor, angiopoietin, ephrin A1, and VEGF and its receptors (Ryuto et al., 1996; Bussolino et al., 1988; Okamura et al., 1991; Giraudo and Primo, 1998; Kim et al., 2000; Cheng and Chen, 2001) . Thus the induction of TP expression by TNFa that we have observed is indicative of another potential mechanism by which the cytokine promotes angiogenesis, and also suggests a means by which colon tumor cells and tumor-associated macrophages interact to influence angiogenesis.
TNFa treatment was found not to increase TP mRNA half-life, suggesting that the enhanced expression of TP mRNA by TNFa was likely mediated at the transcriptional level. This was confirmed by experiments which showed that TP mRNA levels were reduced by treatment of cells with mithramycin, and by the finding that a 1.4-kb 5'-flanking region of TP had promoter activity in WiDr cells both without and with TNFa treatment. Examination of the sequence of the 1.4-kb 5'-flanking region of the TP gene revealed several presumed transcription response elements, including nine Sp1 sites, one AP2 site (7372), one NF1 site (7110), one AML1 site (71123), one SRE site (7971), and two ATF/CREB sites (71186 and 7669). A GAS element (gamma-interferon activated sequence), located at 7423, has been shown to confer responsiveness of the TP gene to interferon g (Goto et al., 2001) , and a putative ISRE (interferon-sensitive response element) (7976) has been suggested to contribute to the induction of the TP gene by interferon a (Schwartz et al., 1998) . Response elements that were not found by sequence analysis in the 1.4-kb 5'-region of the TP gene included AP1, NF-kB, HIF1 and Egr1. In addition to their individual roles in regulating transcription, reports suggest that there is cross-talk between transcription factors, including evidence that gene activation by Sp1 can be modulated by positive and negative interactions with other transcription factors (Hirano et al., 1998; Krehan et al., 2000; Cakouros et al., 2001) . Experiments with constructs containing 5'-truncations of the TP promoter revealed that the transcriptional activity dramatically decreased with deletion of sequence spanning 7368 to 7155 and 7155 to 764. The 64-bp proximal region and the untranslated downstream dC) in the presence of 10 fmol of [g-32 P]ATP endlabeled double-stranded consensus Sp1 probe (5'-ATTCGATCGGGGCGGGGCGAGC-3') (lanes 1 -5), or double-stranded probes for the sequences in the TP promoter for Sp1 site 1 (TP-Sp1 1 ; lanes 6,7,14,15 and 16), site 2 (TP-Sp1 2 ; lanes 8 and 9), site 3 (TPSp1 3 ; lanes 10 and 11), and site 4 (TP-Sp1 4 ; lanes 12 and 13). Oligonucleotide competition experiments were performed in the presence of 50-fold excess of cold Sp1 DNA (lanes 3 and 14) . In some experiments, nuclear extracts were preincubated with 2 ml polyclonal anti-Sp1 antibody (lane 4 and 15) or polyclonal anti-Sp3 antibody (lanes 5 and 16) for 1 h at 48C prior to the addition of labeled DNA probe. Samples were analysed by polyacrylamide gel electrophoresis; dried gels were exposed to X-ray film at 7708C. The arrow indicates the location of an Sp1-specific complex sequences did not contribute to TP transcription. These findings suggest that the essential cis-acting elements may exist in these two regions. The deletion of a DNA stretch, spanning 7369 to 764 bp, caused a loss of most of promoter activity with TNFa treatment. This result further suggests that this region represents the core TNFa-responsive region of the TP promoter. Of the elements noted above, only four of the Sp1 sites and the one NF1 site were found in these critical regions.
Further evidence supporting a role for Sp1 in TP expression has been obtained. Point mutations of the four potential binding sites of Sp1 located in these two regions demonstrated that mutations in three of them substantially reduced TNFa responsiveness. Using an electrophoretic mobility shift assay, these same three sites formed complexes which likely included the Sp1 transcription factor. Nuclear binding activity was higher in WiDr cells with TNFa treatment, consistent with the changes in TP mRNA and enzyme activities seen in the cells. Mithramycin, a DNA-binding agent with some specificity for Sp1 sites, blocked the TNFadependent induction of TP expression (although this could also have been due to an indirect effect subsequent to the inhibition of other genes). Taken together, the data support the conclusion that binding sites within the region 7487 to 764, and Sp1 and/or other members of the Sp-family of transcription factors, were necessary for TNFa to fully induce TP transcription.
Although the TP gene promoter lacks a TATA box, it has been shown that TATA-less promoters still can use TATA factors, and several factors have been proposed to help initiate transcription from TATA-less genes (Smale, 1997) . For example, it has been reported that Sp1 tethers the TATA factor and plays a significant role in transcriptional initiation; it is not known if this is the case for the Sp1 sites in the TP promoter (Pugh and Tjian, 1991) . Genes often have multiple binding sites for Sp1 in close proximity, and Sp1-mediated transcription is also dependent upon the cooperation of other cofactors and transcriptional activators found in complex promoters (Suske, 1999) . Sp1 belongs to a small family of transcription factors which include Sp2, Sp3 and Sp4, which have varying abilities to enhance or repress Sp1-mediated transcription (Naar et al., 1998) . Although the EMSA data suggested that the Sp3 factor was not involved in forming the complexes observed, it is likely that Sp1 is only one of many members of the Sp family and other transcription factor families which contribute to tissue-specific and cytokine-regulated TP expression.
Similar to our observations, induction of expression of VEGF by TNFa was not due to decreased mRNA turnover, although VEGF mRNA stabilization did occur in response to hypoxic stress (Finkenzeller et al., 1995; Ryuto et al., 1996) . It was previously shown that TNFa enhanced the promoter activity of the VEGF gene, which like TP, contains multiple Sp1 binding sites, a cluster of four of which in the proximal promoter were essential for TNFa-dependent activation (Bussolino et al., 1988) . Another study showed that PDGF enhanced VEGF gene expression in NIH3T3 cells, an action that was mediated by the binding of Sp1 and/or Sp3 transcription factors to the 785 to 750 promoter region of the VEGF gene (Finkenzeller et al., 1997) . These findings indicate that both TP and VEGF are similarly regulated by Sp1 binding sites. Indeed, there is a tendency for VEGF and TP to be co-expressed in some human cancers (O'Byrne et al., 2000; Seki et al., 2000) . High expression of both TP and VEGF was found to be a particularly strong prognostic marker in primary breast tumor (Maeda et al., 1996) . Thus the similarity in the transcription regulation of both TP and VEGF provides a molecular explanation for their coexpression in tumor tissue and its clinical consequences. In other instances in which both TP and VEGF levels were measured in the same specimen, however, TP was found to be an independent prognostic factor compared to VEGF, and it may be the primary contributor to angiogenesis in tumors which have low levels of VEGF (Takebayashi et al., 1996; Takahashi et al., 1996) . This suggests that TP and VEGF expression need not always be coordinated, and other factors contribute to their levels of expression.
In addition to its role in angiogenesis, elevated TP expression has also been shown to increase the metabolic activation and the sensitivity of colon carcinoma cells to the cancer chemotherapeutic drug 5-fluorouracil and other fluoropyrimidines (Schwartz et al., 1995) . A similar effect has been shown for the related enzyme uridine phosphorylase, whose expression was also shown to be induced by many of the same cytokines which stimulate TP expression, consequently increasing cell sensitivity to fluoropyrimidines (Eda et al., 1993a; . The promoter of the uridine phosphorylase gene lacks TATA and CCAAT boxes, similar to the TP promoter, and also has been found to contain promoter elements for GATA-1 and -2 transcription factors, interferon regulatory factor 1, the oncogene myb, and the tumor suppressor gene p53 product (Cao et al., 1999; Zhang et al., 2001 ). These observations suggest that there are likely both similarities and differences in the regulation of TP and uridine phosphorylase, and further suggest that their relative levels of expression in tumors are a consequence of the mix of cytokines present and the specific oncogenes and tumor suppressor genes expressed in the tumor.
In summary, we found that the cytokine TNFa transactivates the expression of TP in human colon cancer WiDr cells, and identified the three cisregulatory Sp1 elements which appear to play an essential role in mediating TP's transcriptional activation. These findings indicate that increased expression of the angiogenic factor TP in tumors may be a consequence of cytokine-mediated, tumor cell-inflammatory cell interactions.
Materials and methods

Colon carcinoma cell line
Human colon adenocarcinoma WiDr cells (ATCC, Rockville, MD, USA) were maintained in RPMI 1640 with 10% fetal bovine serum and gentamicin in a humidified CO 2 incubator at 378C. Cells were treated with human recombinant tumor necrosis factor alpha (TNFa), obtained from R&D system Inc. (Minneapolis, MN, USA) .
Measurement of TP enzyme activity
Cells were lysed by sonicating in ice-cold 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, and were centrifuged. TP activity was measured in the supernatants in assays which contained 200 mM KH 2 PO 4 (pH 7.8), 0.2 mM [5'-3 H]-thymidine (50 mCi/mmol) (Moravek Biochemicals), and 50 mg protein. Reactions were stopped after 20 min at 378C by the addition of 0.5 ml of ice-cold activated charcoal in 5% trichloroacetic acid. Using 3 Hthymidine in which the radiolabel is in the deoxyribosyl group yields a product of the TP reaction which did not bind to charcoal, while the substrate thymidine bound tightly (499%). After centrifugation, radioactivity in an aliquot of the supernatant was determined by liquid scintillation counting.
Measurement of TP mRNA levels
RNA was isolated from control and TNFa-treated cells using Trizol Reagent (Life Technologies, Inc.). In some experiments, mithramycin (100 -400 nM) was added for 24 h prior to RNA isolation. For determination of TP mRNA half-life, actinomycin D (10 mg/ml) was used to inhibit mRNA synthesis and estimate mRNA degradation rates. It was added to TNFatreated (20 ng/ml for 48 h) cells, and RNA was isolated at intervals up to an additional 24 h. TP and GAPDH mRNA levels were determined by RT -PCR, as described below. For RT -PCR, 2 mg of total RNA was reverse transcribed into cDNA with 200 units of Maloney leukemia transcriptase (Life Technologies, Inc) in 20 ml of reaction buffer containing 10 units of RNasin, 0.2 mg of random primers, and 0.8 mM dNTPs at 428C for 1 h. Reactions were terminated by heating at 958C for 10 min. The mixture was diluted 2.5 times with RNase-free water. An aliquot (2.5 ml) was used for PCR amplification with primers for TP: sense, 5'-GCTTCGTG-GCCGCTGTGGTG-3', antisense, 5'-TCTGCTCTGGGCTC-TGGATGA-3'; GAPDH: sense, 5'-CATCTCTGCCCTCTG-CTG-3', antisense, 5'-CCCTCCGACGCCTGCTTC AC; and actin: sense, 5'-TCCTGTGGCATCCATGAAACT-3', antisense, 5'-CTTCGTGAACGCCACGTGCTA-3'. The TP primers correspond to sequences in exon 2 and exon 4 of the human genomic TP sequence. Reactions contained 25 ml of 10 mM Tris-HCl, pH 8.3 containing 50 mM KCl, 1.5 mM MgCl 2 , 0.2 mM dNTPs, 0.4 mM of each primers, and 1.25 units of Tag DNA polymerase. The TP reaction proceeded for 30 cycles of denaturation at 948C for 1 min, annealing at 568C for 1 min, and extension at 728C for 1 min. Amplified cDNAs were electrophoresed on 2% agarose gels containing ethidium bromide. Gels were photographed, negatives were scanned on a Molecular Dynamics scanning densitometer, and analysis of band density was done by volume integration using ImageQuant.
Generation of plasmid constructs
To search for DNA elements important for TP expression, PCR was used to produce a fragment from the 5'-flanking region of human TP. The template was genomic TP DNA (pSPDcat), containing a 1.4-kb KpnI/KpnI sequence from the 5'-flanking region and a part of exon 1 (nucleotides 71360 to+64) of the TP gene (kindly provided by Dr K Hagiwara). The PCR primers were sense: 5'-GGGGTACCGAATTCGG-TACCCACCAGGCTCCAC-3', (underlining representing restriction sites for KpnI and EcoRI) and antisense: 5'-GAAGATCTCGGCCTCGCCCGCGGGTC-3', (underlining is restriction site for BglII). The PCR product was subcloned to KpnI and BglII sites of promoterless reporter vector pGL3-basic (Promega, Madison, WI, USA) to allow transcription of firefly luciferase gene under the control of this fragment. 5'-Deletion constructs of the TP promoter were produced by digesting the resultant plasmid with different restriction enzymes, i.e., XhoI, BstEII, StuI, SfiI and SacI. Both 5' overhangs and 3' overhangs were blunted by T4 DNA polymerase (Promega, Madison, WI, USA) and then self-circularized by T4 DNA ligase (Promega, Madison, WI, USA). Various lengths of deletion clones were selected.
Transient transfection
Transient transfection of cultured WiDr was carried out using LipofectAMINE (Life Technologies Inc.). Cells were plated at a density of 1610 5 /well in a 24-well culture plate and transfected the next day. Typically 1 mg of luciferase reporter vector and 10 ng of pRL-CMV internal control construct (Promega, Madison, WI, USA) were transfected with 4 ml of LipofectAMINE. The medium was replaced after 5 h. Twenty-four hours later, cells were stimulated in the presence or absence of 20 ng/ml TNFa for another 48 h. The cells were harvested using 100 ml of passive lysis buffer. Luciferase activity was measured (Dual-Luciferase Assay system, Promega, Madison, WI, USA) and normalized to the internal control. Transfections were performed in triplicate.
Preparation of nuclear extract
Nuclear extracts were prepared as described, with some modifications (Schreiber et al., 1989) . Cells were washed twice with PBS, harvested by scraping into 4 ml of PBS, and centrifuged (500 g, 5 min). The pellet was dispersed in one packed cell volume of hypotonic buffer (10 mM HEPES-KOH, pH 7.9, 10 mM KCl, 1.5 mM MgCl 2 , 1 mM dithiothreitol (DTT), 1 mM phenylmethysulfonyl fluoride (PMSF), aprotinin, pepstatin, and leupeptin, each 2 mg/ml). After 15 min on ice, nonidet P-40 was added to a final concentration of 0.6% (v/v), and nuclei were pelleted by centrifugation (5000 g, 5 min). The pelleted nuclei were dispersed in a high salt buffer (20 mM HEPES-KOH, pH 7.9, 420 mM NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 25% glycerol, 1 mM DTT, 1 mM PMSF, aprotinin, pepstatin, and leupeptin, each 2 mg/ml) to solubilize DNA-binding proteins. The suspended nuclei were gently shaken for 30 min at 48C and centrifuged (12 000 g, 20 min). The cleared supernatants, containing nuclear proteins, were stored in small aliquots at 7708C. Protein concentrations were determined using a Bradford assay kit.
Electrophoretic gel mobility shift assay
Six micrograms of nuclear proteins were incubated with 1 mg each of poly(dl : 5'-GCTTCCCGGGGGCGGCGACTGCCGA-3' Oligonucleotide competition experiments were performed in the presence of 50-fold excess of cold or mutant Sp1 DNA (5'-ATTCGATCGGTTCGGGGCGAGC-3', mutations italicized). In some experiments, nuclear extracts were preincubated with 2 ml polyclonal anti-Sp1 or anti-Sp3 antibodies (PEP-2 and D-20, respectively, Santa Cruz Biotech) for 1 h at 48C prior to the addition of labeled DNA probe. Samples were analysed by polyacrylamide gel electrophoresis; dried gels were exposed to X-ray film at 7708C.
Site-directed mutagenesis
The plasmid pGL3 construct containing the sequence 7487 to +58 of TP promoter was used for oligonucleotide-directed mutagenesis of Sp1 binding sites using the GeneEditor in vitro site-directed mutagenesis system (Promega, San Luis Obispo, CA, USA). The probes were designed to contain a two base pair GC to AT mutation in the core sequence of Sp1, producing the following mutated oligonucleotides:
pGL-Sp1-mut1, GAACCCAGCGGGATGGGGCCCGA-GCG; pGL-Sp1-mut2 ACCCCACCGAGGATGGGAGGGGG-ACTC; pGL-Sp1-mut3 GACCCACGCCGGATGGGACCGGCC-AGG; pGL-Sp1-mut4 AGGCTTCCCGGGGATGGCGACTGC-CGAG.
Following alkaline denaturing from dsDNA to ssDNA, the plasmid pGL3 was annealed with selection and mutagenesis primers. The synthesis of mutant strands was completed with T4 DNA polymerase and circularized T4 DNA ligase. The mixture was initially transformed in repair minus strain of E. coli BMH 71-18 mutS competent cells. A second transformation was performed into E. coli JM 109. Colonies were expanded, and DNA was harvested. The mutation was verified by DNA sequencing and restriction enzyme digestion.
Abbreviations EMSA, electrophoretic mobility shift assay; PD-ECGF, platelet-derived endothelial cell growth factor; TNFa, tumor necrosis factor; TP, thymidine phosphorylase; VEGF, vascular endothelial growth factor
